Naltrexone and pharmacy benefit management

Journal of Addictive Diseases

Volumn 23, Issue 4, 2004, Pages 11-29

  Harris, Katherine M ^a,c   Thomas, Cindy ^b  

^a Substance Abuse Mental Hlth S   (United States)

^b BRANDEIS UNIVERSITY   (United States)

^c Office of Applied Studies   (United States)

Author keywords

Alcohol dependence; Formulary; Naltrexone; Pharmaceutical benefit management; Prescription drug benefits

Indexed keywords

NALTREXONE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; COST BENEFIT ANALYSIS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; PRESCRIPTION; PUBLICATION; REVIEW;

ALCOHOLISM; FORMULARIES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; NALTREXONE; NARCOTIC ANTAGONISTS; PRIVATE SECTOR; PUBLIC SECTOR; UNITED STATES;

EID: 6344241171     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v23n04_02     Document Type: Review

References (34)

1. Fuller RK, Gordis E. Naltrexone treatment for alcohol dependence. New England Journal of Medicine. 2001 Dec 13; 345(24):1770-1.
2. Swift RM. Medications and alcohol craving. Alcohol Research and Health. 1999; 23(3):207-13.
3. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA. 1999 Apr 14;281(14): 1318-25.
4. Horgan CM, Reif S, Ritter GA, Lee MT. Organizational and financial issues in the delivery of substance abuse treatment services. Recent Dev Alcohol. 2001;15:9-26.
5. O'Malley S. 1998. Naltrexone And Alcoholism Treatment: Treatment Improvement Protocol (TIP) Series 28, DHHS, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Rockville, MD. www. health.org/govpubs/BKD268/. Last accessed July 31, 2002.
6. Management of Substance Use Disorders Working Group (MSUDWP). VHA/ DoD clinical practice guideline for the management of substance use disorders. Washington (DC): Veterans Health Administration, Department of Defense: 2001 September.
7. National Institute on Alcoholism and Alcohol Abuse (NIAAA). Alcohol Consumption and Problems in the General Population: Findings from the 1992 National Longitudinal Alcohol Epidemiological Survey, Washington, DC: United States Department of Health And Human Services. 2002.
8. Substance Abuse and Mental Health Services Administration. Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings (Office of Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD. 2002 http://www.samhsa.gov/oas/NHSDA/2k1NHSDA/ vol1/Chapter7.htm. Last assessed December 23, 2002.
9. Mark TL, Kranzler HR, Poole V, Bransberger P, Song X, Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction. 2003 May;98(5):617-26.
10. Thomas CP, Wallack SS, Lee S, McCarty D, Swift R. Research to practice. Adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003 Jan; 24(1):1-11.
11. Kreling DH, Mott DA, Wiederholt JB. Prescription Drug Trends: A Chartbook. Menlo Park, CA: Kaiser Family Foundation. July 2000.
12. William Mercer, Incorporated Prescription Drug Coverage and Formulary Use in California: Different Approaches and Emerging Trends, The California Healthcare Foundation. 2001. http://www.chcf.org/topics/index.cfm?topic=CL116. Last accessed December 23, 2002.
13. Pollard MR, Coster JM. Savings for Medicaid drug spending. Health Affairs. 1991 Summer;10(2):196-206.
14. Bozzette SA, D'Amato R, Morton S, Harris K, Meili R, Taylor R. 2001. Pharmaceutical Technology Assessment for Managed Care: Current Practice and Suggestions for Improvement (MR-1206-SANOFI), Santa Monica, CA: RAND.
15. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991 Oct 10;325(15):1072-7.
16. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994 Sep 8;331(10):650-5.
17. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, McLeod P, Huang A, Larochelle P, Mallet L. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001 Jan 24-31;285(4):421-9.
18. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001 Dec;39(12):1293-1304.
19. Schulman KA, Rubenstein LE. Abernethy DR, Seils DM, Sulmasy DP. The effect of pharmaceutical benefits managers: Is it being evaluated? Ann Intern Med. 1996 May 15;124(10):906-13.
20. Substance Abuse and Mental Health Services Administration (SAMHSA). 2000. State Profiles, 1999, on Public Sector Managed Behavioral Health Care. Rockville, MD: United States Department of Health and Human Services (DHHS Publication Number (SMA) 00-3432.
21. Rogowski JA. Insurance coverage for drug abuse. Health Affairs. 1992 Fall; 11(3):137-48.
22. Schneider A, Rachel Garfield. Medicaid Benefits. Kaiser Commission on Medicaid and the Uninsured, Issue Paper: Washington, DC. August 2000.
23. National Pharmaceutical Council, Incorporated. Pharmaceutical Benefits Under State Medical Assistance Programs. 2001. Author: Reston, VA.
24. Coffey RM, King MT, Harwood H, McKusick D, Genuardi J, Dilonardo J, Buck JA. National Expenditures for Mental Health and Substance Abuse Treatment, 1997, SAMHSA Publication No. SMA-00-3499. Rockville, MD: United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, July 2000.
25. United States Department of Veterans Affairs (VA) 2002. Facts about the Department of Veterans Affairs. http://www.va.gov/pressrel/vafacts.htm. Last accessed December 26, 2002.
26. Wilson NJ, Kizer KW. The VA health care system: An unrecognized national safety net. Health Affairs. 1997; 16(4): 200-04.
27. Chen S, Wagner TH, Barnett PG. The effect of reforms on spending for veterans' substance abuse treatment. Health Affairs, 2001; 20(4):169-75.
28. Wilson NJ, Kizer KW. The VA health care system: an unrecognized national safety net. Health Affairs. 1997; 16(4): 200-04.
29. VA Naltrexone Policy Taskforce: Policy Review by the Naltrexone Task Force of the Department of Veterans Affairs. April 2, 2002. Unpublished memorandum.
30. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001 Dec 13;345(24):1734-9.
31. United States Department of Defense (DoD) Policy Memorandum on TRICARE Substance Abuse Treatment, Assistance Secretary of Defense, Health Affairs, 1997. (http://www.tricare.osd.mil/policy/fy97/abus9729.html). Last accessed December 26, 2002.
32. United States Office of Personnel Management (OPM). Guide to Federal Employees' Health Benefit Plans. Retirement and Insurance Service. 2002www.opm.gov/ inusre. Last accessed December 26, 2002.
33. Butler SM, Moffit RE. The FEHBP as a model for a new Medicare program. Health Affairs. 1995; 14(4): 47-61.
34. ROW Sciences. Evaluation of Parity in the Federal Employees Health Benefit Program: Evaluation Design Report (Contract No. HHS-100-00-0025). May 2001.